Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">SGLT2i (+MET) versus SU (+MET)</td><td class="align_center">Percentage of patients with NSHEs in SU arm (%)</td><td class="align_center">Percentage of patients with NSHEs in SGLT2i arm (%)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">Dapagliflozin versus glipizide [<a href="/journals/ije/2018/3718958/#B19" target="_blank">19</a>]</td><td class="align_center">39</td><td class="align_center">3.4</td></tr><tr><td class="align_left">Canagliflozin versus glimepiride [<a href="/journals/ije/2018/3718958/#B21" target="_blank">21</a>]</td><td class="align_center">31</td><td class="align_center">5</td></tr><tr><td class="align_left">Empagliflozin versus glimepiride [<a href="/journals/ije/2018/3718958/#B23" target="_blank">23</a>]</td><td class="align_center">20</td><td class="align_center">1.5</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Extracted data from selected RCTs on SU versus SGLT2i as an add-on to metformin.</div>

International Journal of Endocrinology

tab1

Table 1

Table 1: Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective 

Table 1 | Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective 